Citations

Abstract Emotional experiences during focal seizures are often misinterpreted as psychiatric disorders. We aimed to evaluate symptoms involving affective symptoms at seizure onset. We aimed to identify the most prevalent affective symptoms at seizure onset and characterize their localizing and lateralizing value. We performed a scoping review based on Preferred Reporting Items for Systematic reviews and Meta‐Analyses–extension for Scoping Reviews guidelines. A systematic search identified records from 4 databases: PubMed, Embase, CINAHL (via EBSCOhost), and Web of Science. Two reviewers independently screened titles/abstracts and full texts; discrepancies were resolved by consensus. This review focused on patients with focal seizures, as affective symptoms may occur in generalized epilepsies. The affective symptoms: fear, anxiety, panic, sadness, mystic, ecstatic, sexual, and mirth were identified, and semiology was evaluated in accordance with ILAE guidelines. Symptom onset, frequency, brain localization, and video‐EEG monitoring technique were evaluated to assess localization and lateralization of regional networks. Scalp EEG, invasive EEG recordings, and electrical stimulation were analyzed. A total of 1276 documents were identified, with 98 studies included for review. Fear was the most frequently reported ictal emotion, identified in 274 patients (66%), predominantly in temporal lobe epilepsy. Sadness and sexual, ecstatic symptoms were also consistently associated with temporal networks. Mirth was more frequently reported with frontal onset seizures. Evidence, primarily from Class IV studies, reported right hemispheric predominance for ecstasy, mystic, and sexual symptoms at seizure onset. Ictal affective symptoms at seizure onset yield localizing information. The limbic system, especially the temporal lobe, followed by the frontal lobe, was the most common site of origin. Fear was the most common spontaneous and electrically elicited symptom, followed by anxiety. While bi‐hemispheric lateralization occurred, right lateralization predominated. Recognizing paroxysmal affective symptoms as ictal phenomena may reduce misdiagnosis and aid presurgical evaluation in drug‐resistant focal epilepsy.

Abstract Chronic kidney disease (CKD) is one of the most prevalent diseases in feline medicine. Mass spectrometry-based urinary proteomics offers powerful insight into biomarker candidates and disease subtyping in CKD by measuring protein profiles rather than individual proteins. This study aims to measure the urinary proteome to identify protein profiles in cats with and without CKD to gain pathophysiological insights into the disease and more precisely diagnose CKD. Here, we identify 2,219 urinary proteins in the feline urinary proteome. Using univariate biomarker analysis, we show that MMP-7 may be a promising biomarker of CKD in cats. We then demonstrate the power of using protein profiles rather than individual proteins by grouping proteins based on how they trend across disease states. The changes to the global urinary proteomes of individual cats showed three distinct groups of CKD cats with unique protein profiles, suggesting that different pathophysiological mechanisms mediate disease subtypes. We demonstrate that large-scale urinary proteomics may provide a powerful framework for discovering candidate biomarkers that advance the subtyping and mechanistic understanding of feline CKD.

Aims: The aims of this study were to evaluate the association between the red cell distribution width (RDW)–albumin ratio (RAR) and subclinical myocardial impairment, as assessed by left ventricular global longitudinal strain (LVGLS), and to examine the relationships between the RAR, heart failure (HF) hospitalization, and all-cause mortality. Methods: We conducted a retrospective cohort study on adults who underwent transthoracic echocardiography (TTE) with LVGLS assessment across three Mayo Clinic centers (2017–2024) and who had RDW and serum albumin measured on the same day or within seven days. The RAR was calculated as RDW/albumin and categorized into the following tertiles: <2.93, 2.93–3.48, and >3.48. Impaired LVGLS was defined as >−18%. Associations between the RAR and outcomes were assessed using multivariable logistic regression (LVGLS) and Cox models (HF and mortality), adjusting for demographics and comorbidities. Results: Among 5069 patients, 39.7% had impaired LVGLS, and its prevalence increased across RAR tertiles (26.8%, 41.9%, and 51.1%). Adjusted odds ratios for impaired LVGLS were 1.74 and 2.30 for tertiles 2 and 3, respectively. A higher RAR was associated with increased risk of HF hospitalization (aHR 2.54 and 4.48) and all-cause mortality (aHR 2.39 and 7.30). These associations persisted after adjusting for LVGLS. The effect of the RAR on mortality was stronger in patients with normal LVGLS compared to those with impaired LVGLS (p for interaction = 0.0004). Conclusions: A higher RAR was associated with abnormal LVGLS, HF hospitalization, and all-cause mortality after adjustment for clinical risk factors. However, the RAR did not provide discriminative value beyond its individual components.

Purpose To compare radiographically the concavity depth and slope angle of the congruent‐arc distal tibial allograft (CA‐DTA), harvested from the posterior distal tibia, with the traditional lateral distal tibial allograft (traditional DTA) used for glenoid reconstruction in anterior shoulder instability with bone loss. Methods A convenience sample of 32 ankle computed tomography scans from patients ≤35 years old without prior trauma, arthritis, or ankle pathology were retrospectively reviewed. Using standardized coronal (traditional DTA) and sagittal (CA‐DTA) reconstructions, 2 independent reviewers measured allograft concavity depth (mm) and slope angle. Paired t tests compared traditional versus CA‐DTA measurements. Intraclass correlation coefficients assessed reliability. Significance was set at P < .05. Results The mean age of patients was 25.2 years, with 50% (n = 18) of patients being male. Compared with the traditional DTA, the CA‐DTA showed significantly greater glenoid concavity change (2.9 ± 0.65 mm vs −2.3 ± 0.71 mm; P < .001) and slope angle (22.9°± 4.02 vs −9.78°± 4.07; P < .001). All CA‐DTAs showed positive concavity and slope, whereas all traditional DTAs produced negative values. Conclusions The CA‐DTA consistently increased both concavity and slope, whereas the traditional DTA decreased these measures. By leveraging the posterior tibial surface, the CA‐DTA more reliably recreates the anatomic “half‐pipe” glenoid contour that contributes to bony concavity‐compression‐based stability. Clinical Relevance The CA‐DTA offers a graft alternative that more reliably restores glenoid concavity in anterior shoulder instability with glenoid bone loss. This has potential implications for improved glenohumeral stability and clinical outcomes.

OBJECTIVE Primary malignant osseous tumors of the mobile spine are rare and require complex, multidisciplinary care. Treatment outcomes may differ between academic and community hospitals due to variations in resources, expertise, and infrastructure. This study evaluates demographics, care delivery patterns, and clinical outcomes, including both short- and long-term survival, for patients treated at academic versus community cancer programs using the National Cancer Database. METHODS A retrospective analysis of a prospectively maintained database was performed. Nine hundred forty-three patients diagnosed with primary malignant osseous tumors of the mobile spine between 2004 and 2017 were identified. Patients were stratified by facility type: there were 601 patients treated at academic comprehensive cancer programs (ACADs) and 342 treated at comprehensive community cancer programs (CCCPs). Demographic, treatment, and clinical data were compared using descriptive statistics. Outcomes included inpatient length of stay, time to treatment, 30- and 90-day mortality, vital status at last contact, and overall survival. A multivariable Cox proportional hazards model assessed factors associated with overall survival. RESULTS Patients at ACADs were significantly younger and more likely to have private insurance. The size and histopathological composition of the tumors did not differ significantly between facility types. ACAD patients experienced significantly longer inpatient stays and longer time to radiation initiation among patients receiving radiation with documented start dates. Time to chemotherapy did not significantly differ (p = 0.91). Thirty- and 90-day mortality were comparable between facility types among eligible surgical cases. At last follow-up, a significantly greater proportion of ACAD patients were alive (50.2% vs 38.3%, p < 0.001), and the median time from diagnosis to last contact or death was longer at ACADs (40.8 vs 33.2 months, p = 0.001). In the primary multivariable Cox model, treatment at an academic facility was associated with improved overall survival (hazard ratio [HR] 0.766, 95% CI 0.627–0.937; p = 0.009). In a sensitivity model adjusting for histopathology rather than grade, this association was attenuated and no longer statistically significant (CCCP vs ACAD, HR 1.19, p = 0.081). CONCLUSIONS Patients treated at academic centers had longer inpatient stays and longer time to radiation initiation, yet academic facility treatment was associated with improved overall survival in the primary multivariable model. After accounting for histopathological subtype in sensitivity analysis, the facility-type association was attenuated, suggesting survival differences reflect both tumor biology and system-level care pathways.

Abstract Positron emission tomography (PET)-based molecular imaging is a clinically important tool for the evaluation of dementia and other neurodegenerative disorders, using radiotracers that target specific molecular and pathophysiological processes. Fluorodeoxyglucose brain PET has historically supported neurodegenerative disorder evaluation through detection of characteristic patterns of regional glucose hypometabolism. In recent years, the molecular imaging of protein aggregates has taken on an increasingly important role. This is evident with the widespread clinical adoption of amyloid PET and early use of tau PET to provide diagnostic and prognostic information for patients with suspected Alzheimer’s disease. Additional classes of radiotracers relevant to neurodegenerative diseases are under active investigation, including those targeting neuroinflammation, synaptic density, and α-synuclein aggregates. We review the major classes of PET radiotracers for neurodegenerative diseases, describing their molecular mechanisms, diagnostic performance, and their current and emerging clinical roles in dementia evaluation. Case examples for clinically used tracers illustrate imaging features relevant to diagnosis and characterization of prognosis and treatment effect. Finally, we discuss early developments and current challenges in the development of theranostic approaches and novel radiotracers for neurodegenerative diseases.

Klippel-Trénaunay syndrome (KTS) is a rare congenital vascular-overgrowth disorder within the broader spectrum of PIK3CA -related overgrowth syndromes. Although clinical, radiologic, and orthopedic manifestations are well described, the histologic spectrum of KTS-associated pathology remains under-characterized. Clinicopathologic findings from 21 patients with clinically established KTS were reviewed, including 18 with longitudinal clinical follow-up and 3 consultation cases of rare malignant mesenchymal neoplasms. Cases were identified from institutional pathology and clinical databases, and available hematoxylin and eosin-stained sections and ancillary studies were reviewed. The cohort included 11 males and 10 females. Among the 18 clinically followed patients, 12 had limb length discrepancy or asymmetric limb overgrowth, 9 had documented deep vascular malformations, 4 had intra-articular/synovial malformations, and 10 underwent initial orthopedic evaluation or intervention before age 18. Orthopedic morbidity clustered into mechanical overgrowth-related, vascular malformation-related, and soft tissue/wound-related complications. Histologic findings included superficial and/or deep slow-flow vascular malformations, ulceration and granulation tissue, hemosiderin-laden reactive synovium, and destructive hemorrhagic arthropathy. Intra-articular disease recapitulated a hemophilic arthropathy-like pattern, with hemosiderotic synovitis, papillary synovial hyperplasia, and progressive joint destruction with loss of articular cartilage, exposed subchondral bone destruction and remodeling, all attributable to long-standing intra-articular hemorrhage. Three consultation cases showed malignant mesenchymal neoplasia, including 2 angiosarcomas. Recognition of these patterns is important for pathologists evaluating specimens from patients with known or suspected KTS, particularly when findings mimic hemophilic arthropathy, diffuse-type tenosynovial giant cell tumor, nonsyndromic vascular malformation, and/or end-stage destructive arthropathy.

Introduction The World Health Organization (WHO) endorses male circumcision as an effective human immunodeficiency virus (HIV) prevention intervention in settings where the expected impact is greatest, including Sub-Saharan Africa. Data on cost implications of early infant male circumcision (EIMC) are limited. The ShangRing (SR) is a WHO pre-qualified device for circumcision. We sought to perform a comprehensive cost assessment alongside a randomized controlled trial (RCT) of the SR versus the standard of care Mogen clamp (MoC) for EIMC to enable future scale-up towards a cost-effective HIV prevention strategy. Methods We collected resource utilization and economic data as part of an RCT of infants aged 0–60 days old undergoing EIMC in Kenya, Tanzania, and Uganda. Cost data for both the SR and MoC included baseline facility costs, direct costs, and indirect costs. The Decision Makers Program Planning Tool v1.0 was used to perform a direct cost comparison of these two devices. The Goals model was used to compare the costs of EIMC in 2023 using the present value of money to circumcise an adolescent male 15 years from now. Results A total of 1,378 infant males underwent circumcision, 689 via SR and 689 via MoC. The overall cost of a single EIMC in Kenya, Tanzania, and Uganda were 61.30 United States Dollars ($), $47.14, and $64.59 respectively for the SR, and $56.38, $50.43, and $58.57 respectively for the MoC. In Kenya, EIMC would be less expensive based on nominal present costs in 2023 compared to waiting for adolescent circumcision at age 15 years in 2038. This finding is reversed in Tanzania and Uganda. Conclusions The overall cost of EIMC via SR versus MoC is comparable in an RCT. With scale-up utilizing lower level personnel, the cost of SR may be further reduced. The SR is an attractive alternative for future EIMC initiatives in Sub-Saharan Africa to further reduce HIV burden.

Abstract Background Lower extremity compression therapy has been proposed as an adjunct to mitigate diuretic resistance during acute decompensation of heart failure (ADHF). We evaluated the effect of lower leg compression with elastic bandages on diuretic efficiency in patients with diuretic-resistant ADHF. Methods Historical cohort study enrolling adult cardiac ICU admissions with ADHF who used elastic bandages (EB) at Mayo Clinic in Minnesota from 2007 to 2017. The diuretic efficiency before and after applying EB was the primary outcome. Results A total of 176 patients with heart failure who received elastic bandages were included. The in-hospital mortality rate, the median hospital length of stay, and 30-day hospital readmission were 9.7%, 11.4 days (IQR 7.1–19.0), and 11%, respectively. When EB was applied, the average daily loop diuretic dosage was decreased by a mean difference of 1.19 mg per 40 mg furosemide equivalent (95% CI: 0.22 to 2.2; p = 0.016). The average post-EB diuretic efficiency was 1,355 mL (IQR 1,119, 1,590) per 40-mg furosemide, which was significantly higher than before EB application, with a mean difference of 340 mL per 40-mg furosemide equivalent (95% CI: -554, -125; p = 0.002). A higher diuretic efficiency led to lower diuretic doses. Average daily urine output before and after EB application was not different (2,642 pre-EB vs. 2,792 post-EB mL/day; 95% CI: -455 to 154; p = 0.33). Conclusion EB use enhances diuretic efficacy during ADHF. Further studies are needed to determine the potential clinical benefits and risks of applying EB compression treatment in ADHF.